Overview

A Study of ASN007 in Patients With Advanced Solid Tumors

Status:
Completed
Trial end date:
2020-06-30
Target enrollment:
Participant gender:
Summary
The study is divided into two parts. The first part of the study will test various doses of ASN007 to find out the highest safe dose to test in five specific groups. The second part of the study will test how well ASN007 can control cancer.
Phase:
Phase 1
Details
Lead Sponsor:
Asana BioSciences